Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. (Q48818299)
Jump to navigation
Jump to search
scientific article published on 11 May 2010
Language | Label | Description | Also known as |
---|---|---|---|
English | Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. |
scientific article published on 11 May 2010 |
Statements
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial (English)
Richard G Langley
Chenglong Han
Brad Schenkel
Philippe Szapary
Ming-Chun Hsu
Jean-Paul Ortonne
Kenneth B Gordon